Kirk Sean 4
4 · Emergent BioSolutions Inc. · Filed Apr 8, 2020
Insider Transaction Report
Form 4
Kirk Sean
EVP, Manufacturing & Tech Ops
Transactions
- Sale
Common Stock
2020-04-06$60.00/sh−5,666$339,960→ 12,571 total - Exercise/Conversion
Common Stock
2020-04-06$30.63/sh+7,293$223,385→ 19,864 total - Sale
Common Stock
2020-04-06$60.00/sh−7,293$437,580→ 12,571 total - Exercise/Conversion
Common Stock
2020-04-06$30.86/sh+3,135$96,746→ 15,706 total - Sale
Common Stock
2020-04-06$60.00/sh−3,135$188,100→ 12,571 total - Sale
Employee Stock Options (Right to Buy)
2020-04-06$60.00/sh−3,135$188,100→ 38,805 totalExercise: $30.86Exp: 2021-02-28→ Employee Stock Options (Right to Buy) (3,135 underlying) - Sale
Employee Stock Options (Right to Buy)
2020-04-06$60.00/sh−7,293$437,580→ 31,512 totalExercise: $30.63Exp: 2022-02-27→ Employee Stock Options (Right to Buy) (7,293 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk.
- [F2]Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated.
- [F3]The options vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company.